EUCTR2016-003292-22-DE进行中（未招募）1 期
A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of ianalumab doses administered subcutaneously in patients with moderate to severe primary Sjogren’s Syndrome
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Fulfilled revised American European US Consensus Group
- •criteria for pSS
- •- Seropositive at screening for anti-Ro/SSA antibodies
- •- Other protocol-defined inclusion/exclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 126
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 54
排除标准
- •- Secondary Sjogren’s syndrome
- •- Use of other investigational drugs
- •- Active viral, bacterial or other infections
- •- Positive hepatitis B, hepatitis C, HIV or tuberculosis test results at
- •- Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in Psoriatic Arthritis and axial Spondyloarthritis patients withactive enthesitis including one Achilles tendon site (ACHILLES)Psoriatic arthritisAxial spondyloarthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 21.1Level: PTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2016-000972-91-GBovartis Pharma Services AG204
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in patients with non-radiographic axial spondyloarthritis.on-radiographic axial spondyloarthritisMedDRA version: 20.0Level: LLTClassification code 10076297Term: Non-radiographic axial spondyloarthritisSystem Organ Class: 100000004859EUCTR2015-001106-33-ITOVARTIS PHARMA SERVICES AG555
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in patients with non-radiographic axial spondyloarthritisEUCTR2015-001106-33-ESovartis Farmacéutica S.A.555
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in Psoriatic Arthritis and axial Spondyloarthritis patients with active enthesitis including one Achilles tendon site (ACHILLES)Psoriatic arthritis Axial spondyloarthritisMedDRA version: 19.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.0 Level: PT Classification code 10071400 Term: Axial spondyloarthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2016-000972-91-SKovartis Pharma Services AG200
已完成
3 期
A randomized, double-blind, placebo-controlled multicenter study of secukinumab 150 mg in patients with active non-radiographic axial spondyloarthritis to evaluate the safety, tolerability and efficacy up to 2 years, followed by an optimal phase of either 150 mg or 300 mg randomized dose escalation for up to another 2 yearsnon-radiographic spondyloartritis10023213NL-OMON47618ovartis12